A panel of analysts and investors have told a conference that the threat of biosimilars to the reference drug manufacturers should not be underestimated.
The panellists at The Financial Times Pharmaceutical and Biotechnology Conference 2017 were discussing how markets view the future for the industry.
They singled out some of the big-selling biologics that are either already facing competition in major markets, or are fighting to hold off other market entrants.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze